Investment analysts at StockNews.com initiated coverage on shares of ADMA Biologics (NASDAQ:ADMA – Get Rating) in a research note issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Separately, HC Wainwright restated a “buy” rating and issued a $4.50 price target on shares of ADMA Biologics in a research note on Wednesday, February 8th.
ADMA Biologics Trading Down 2.8 %
ADMA opened at $3.13 on Thursday. The company’s 50 day moving average is $3.51 and its 200-day moving average is $3.17. ADMA Biologics has a 1-year low of $1.43 and a 1-year high of $3.98. The company has a current ratio of 5.04, a quick ratio of 1.38 and a debt-to-equity ratio of 1.51. The company has a market cap of $615.92 million, a P/E ratio of -8.46 and a beta of 0.87.
Institutional Investors Weigh In On ADMA Biologics
ADMA Biologics Company Profile
ADMA Biologics, Inc operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations.
- Get a free copy of the StockNews.com research report on ADMA Biologics (ADMA)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.